We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $20.9M
1-Year Est. Return 195.52%
This Fund
S&P 500
This Quarter Est. Return
+8.75%
1 Year Est. Return
+195.52%
3 Year Est. Return
+318.83%
5 Year Est. Return
+369%
10 Year Est. Return
+2,361.28%
AUM
$44.9M
AUM Growth
-$9.95M
Cap. Flow
-$7.97M
Cap. Flow %
-17.75%
Top 10 Hldgs %
83.47%
Holding
31
New
4
Increased
3
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$1.38M
2
BLUE
bluebird bio
BLUE
+$748K
3
IRON icon
Disc Medicine
IRON
+$362K
4
BNTC icon
Benitec Biopharma
BNTC
+$349K
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$346K

Top Sells

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$2.87M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.98M
3
INSM icon
Insmed
INSM
+$1.34M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.15M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 55.38%
2 Miscellaneous 44.49%
3 Technology 0.1%
4 Communication Services 0.04%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.5B
$18.2M 40.58%
82,500
– –
INSM icon
2
Insmed
INSM
$27.6B
$3.81M 8.49%
52,200
-18,135
-26% -$1.34M
GERN icon
3
Geron
GERN
$1.01B
$2.86M 6.37%
630,000
– –
ARDX icon
4
Ardelyx
ARDX
$976M
$2.55M 5.68%
370,000
-486,667
-57% -$2.87M
MIST icon
5
Milestone Pharmaceuticals
MIST
$149M
$2.51M 5.6%
1,654,154
-686,053
-29% -$998K
BHVN icon
6
Biohaven
BHVN
$2.37B
$1.77M 3.94%
+35,400
New +$1.38M
MIRM icon
7
PUT
Mirum Pharmaceuticals
MIRM
$6.15B
$1.75M 3.91%
45,000
– –
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$6.08B
$1.53M 3.42%
61,400
-43,291
-41% -$1.05M
BBIO icon
9
BridgeBio Pharma
BBIO
$14.6B
$1.25M 2.78%
49,000
– –
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.22M 2.72%
693,778
-1,421,049
-67% -$1.98M
FENC icon
11
Fennec Pharmaceuticals
FENC
$434M
$1.07M 2.39%
215,000
+45,000
+26% +$260K
MLYS icon
12
Mineralys Therapeutics
MLYS
$2.49B
$957K 2.13%
79,000
– –
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.84B
$889K 1.98%
46,200
-18,800
-29% -$388K
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$839K 1.87%
64,000
-18,500
-22% -$282K
BLUE
15
DELISTED
bluebird bio
BLUE
$820K 1.83%
78,913
+45,000
+133% +$748K
RGNX icon
16
Regenxbio
RGNX
$590M
$606K 1.35%
57,750
+21,500
+59% +$262K
JSPR icon
17
Jasper Therapeutics
JSPR
$23.6M
$602K 1.34%
32,000
– –
IRON icon
18
Disc Medicine
IRON
$3.04B
$378K 0.84%
+7,700
New +$362K
BNTC icon
19
Benitec Biopharma
BNTC
$436M
$358K 0.8%
+39,000
New +$349K
ARQT icon
20
Arcutis Biotherapeutics
ARQT
$3B
$326K 0.73%
+35,100
New +$346K
MCRB icon
21
Seres Therapeutics
MCRB
$57.5M
$322K 0.72%
17,038
– –
LUMO
22
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$153K 0.34%
39,589
-51,205
-56% -$142K
MSFT icon
23
Microsoft
MSFT
$3.71T
$43K 0.1%
100
– –
SPRB
24
Spruce Biosciences
SPRB
$166M
$35.6K 0.08%
1,000
– –
GOOG icon
25
Alphabet (Google) Class C
GOOG
$4.1T
$16.7K 0.04%
100
– –
1
2

Similar funds

SCM
Stadium Capital Management New Canaan, Connecticut $21M AUM 6.45% 1-Year Est. Return
MPW
MGO Private Wealth Irvine, California $20.7M AUM 18.57% 1-Year Est. Return
FS
Financially Speaking Greenwood Village, Colorado $20.6M AUM 16.79% 1-Year Est. Return
VAM
Vazirani Asset Management New York $20.3M AUM 79.33% 1-Year Est. Return
SPC
Stone Point Capital Greenwich, Connecticut $21.7M AUM 48.55% 1-Year Est. Return
SCM
Semanteon Capital Management Newton, Massachusetts $22.2M AUM 53.69% 1-Year Est. Return
HIIL
HS Investments III Ltd St. Peter Port $22.3M AUM
PMAM
Penn Mutual Asset Management Conshohocken, Pennsylvania $19.5M AUM 3.07% 1-Year Est. Return

Lion Point Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Lion Point Capital held 31 positions worth $44.9M, down 18% from $54.9M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Lion Point Capital withdrew a net $7.97M in Q3 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $1.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 55% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Lion Point Capital opened a new position in Biohaven worth $1.77M.

  • Lion Point Capital's largest Q3 2024 buy was Biohaven: 35,400 shares worth $1.77M.
  • Lion Point Capital added most to bluebird bio in Q3 2024, an estimated $748K increase.
  • Lion Point Capital's biggest Q3 2024 reduction was Ardelyx, cutting an estimated $2.87M.
  • Lion Point Capital fully exited Neurocrine Biosciences in Q3 2024, selling an estimated $1.15M.
  • Lion Point Capital's ten largest holdings make up 83% of its $44.9M portfolio in Q3 2024.
  • Lion Point Capital opened 4 new positions and closed 6 in Q3 2024.
  • Lion Point Capital's portfolio value fell 18% quarter-over-quarter to $44.9M.

Based on Lion Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.